



# **Renalytix to Present at Growth Stock Conference**

June 8, 2022

RNS Number : 07400

Renalytix PLC

08 June 2022

**Renalytix to Present at 42<sup>nd</sup> Annual William Blair Growth Stock Conference**

**NEW YORK and SALT LAKE CITY, June 8, 2022** -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42<sup>nd</sup> Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at [investors.renalytix.com](http://investors.renalytix.com).

***For further information, please contact:***

**Renalytix plc**  
James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)  
Via Walbrook PR

**Stifel (Nominated Adviser, Joint Broker)**  
Alex Price / Nicholas Moore

Tel: 020 7710 7600

**Investec Bank plc (Joint Broker)**  
Gary Clarence / Daniel Adams

Tel: 020 7597 4000

**Walbrook PR Limited**  
Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

**CapComm Partners**  
Peter DeNardo

Tel: 415-389-6400 or [investors.renalytix.com](http://investors.renalytix.com)

**About Renalytix**

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis<sup>TM</sup> for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFRMMTMTIMTPT